EvolveImmune to Present Preclinical Data on EVOLVE T Cell Engager at SITC Annual Meeting

EvolveImmune Therapeutics, based in Branford, Connecticut, has announced the upcoming presentation of new preclinical data at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, from November 6-10, 2024. The company, which focuses on developing innovative biotherapeutics to tackle cancer cell resistance to immune therapies, will highlight the latest findings on its EVOLVE platform. This platform is designed to enhance T cell engagement and co-stimulation, thereby increasing the effectiveness of cancer immunotherapy.

The lead candidate, EVOLVE104, is under development for treating solid tumors. It leverages a novel costimulatory T cell engager platform that integrates CD2 co-stimulation. This approach aims to boost the tumor-killing ability of T cells while overcoming challenges related to low tumor immunogenicity and T cell dysfunction. By doing so, it seeks to conditionally activate adaptive immunity and target cancer cells more effectively.

Two poster presentations will highlight the recent preclinical data for EVOLVE104. These include evidence of its safety and efficacy in preclinical models, particularly its ability to target ULBP2/5/6, which are proteins found on certain tumor cells. The presentations will cover updated RNA and immunohistochemistry analyses across various solid tumors, identifying those most likely to respond to EVOLVE104. This data suggests that EVOLVE104 could offer clinical advantages over existing immunotherapies.

The company is progressing with its chemistry, manufacturing, and control (CMC) activities for EVOLVE104, aiming to initiate clinical trials in 2025. This progress underscores EvolveImmune’s commitment to advancing its therapeutic candidates toward clinical application.

Additionally, EvolveImmune will present data on EVOLVE205, another promising candidate targeting CD20. EVOLVE205 is engineered in a 2:1 bispecific format, designed to treat hematologic tumors and B cell malignancies. The oral presentation will discuss its preclinical activity, showcasing its potential differentiation from approved CD20-targeted therapies. This highlights the versatility and expanding potential of the EVOLVE platform to serve as a foundation for new classes of T cell engager therapies.

Dr. Jay Fine, President of Research and Development at EvolveImmune, expressed optimism about the clinical potential of EVOLVE104 and the broader capabilities of the EVOLVE platform. The upcoming SITC conference provides an opportunity for the company to share its progress and breakthroughs with the scientific community.

Details of the SITC presentations include:

1. EVOLVE104 Poster Presentations:
- Title: "EVOLVE104, a first-in-class novel ULBP2/5/6-targeting T cell engager with integrated CD2 co-stimulation, demonstrates a favorable preclinical safety and toxicity profile in cynomolgus monkeys"
- Presenter: Antonio Ward, Ph.D.
- Session: Novel Single-Agent Immunotherapies
- Date/Time: Friday, November 8, 2024, from 9:00 a.m. – 7:00 p.m. CST
- Location: Poster Hall in Exhibit Halls A and B of the George R. Brown Convention Center

- Title: "Precision oncology strategy for EVOLVE-104, a differentiated T cell engager for the novel solid tumor target ULBP2/5/6"
- Presenter: Oksana Sergeeva, Ph.D.
- Session: Novel Single-Agent Immunotherapies
- Date/Time: Friday, November 8, 2024, from 9:00 a.m. – 7:00 p.m. CST
- Location: Poster Hall in Exhibit Halls A and B of the George R. Brown Convention Center

2. EVOLVE205 Oral Presentation:
- Title: "EVOLVE205, a highly potent 2:1 CD20-targeted CD2 co-stimulatory T cell engager engineered for the treatment of B cell malignancies and B cell autoimmune diseases"
- Presenter: Afsana Sabrin, Ph.D.
- Session: CAR-T Cells vs T-cell Engineering Bispecifics in Hematological Malignancies
- Date/Time: Saturday, November 9, 2024, from 5:15 - 6:35 p.m. CST
- Location: Level 3 - Grand Ballroom A of the George R. Brown Convention Center

EvolveImmune Therapeutics is dedicated to developing pioneering immunotherapy solutions to combat various cancers, with first-in-human clinical trials expected in 2025. The company benefits from the support of prominent investors such as Pfizer Ventures, Solasta Ventures, Bristol Myers Squibb, Takeda Ventures, Inc., Yonjin Ventures, and Elm Street Ventures.